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Primary  angiosarcoma  (AS)  of  the breast  is a  rare  neoplasia  that  is  not  related  to  radiation  exposure.
It  represents  less  than  0.05%  of  all malignant  breast  tumors.  This  lesion  is  characterized  by aggressive




Currently  there  are  not  evidence-based  guidelines  regarding  surgical  and  adjuvant  treatment  for  this
tumor  even  though  wide  surgical  resection  followed  by  chemo-  radiotherapy  appears  to  improve  both
disease  free  survival  and  overall  survival.
The aim  of this  study  was  to analyze  the  available  series  of  AS  patients  suggesting  the  most  reliable
treatment  options  for this  rare  neoplasia.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  on behalf  of IJS  Publishing  Group  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Primary breast sarcomas are rare conditions that present
n histological heterogeneity. They are mostly represented by
brosarcomas, angiosarcomas, myxoid/round cell liposarcomas,
hyllodes tumors and malignant ﬁbrous histiocytomas [1].
Angiosarcoma (AS) of the breast represents 1% of all soft tissue
reast tumors. It arises from the connective breast tissues and may
xtend into the overlying skin [2].
AS can arise de novo with a median age at onset of 40 years
r can be secondary to radiation treatment of an epithelial breast
ancer with a median onset age of 70 years (median of 10.5 years
fter radiotherapy) [3–5].The overall incidence rate of primary angiosarcomas is less than
.05% of all malignant breast tumors. Borrman in 1907 described
he ﬁrst documented case of breast angiosarcoma [6].
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Three main histopathological patterns have been described:
type I, characterized by vascular channels invading the breast tissue
with scarce endothelial proliferation; type II, presenting patterns
of papillary endothelial components and type III, with evidence of
endothelial components, necrosis and hemorrhage [7].
Available literature reports many papers focusing on post-
radiation angiosarcomas but only small series of patients affected
by primary angiosarcoma are presented.
The aim of our review is to verify if there is a correlation between
histopathological–clinical features and patient outcomes.
We selected articles from the PubMed database using search
terms “primary”, “angiosarcoma” and “breast”. We found 297
English language papers. We  reviewed all abstracts and reviewed
the available evidence.
2. Presentation and diagnosis
Primary AS usually presents as a poor deﬁned mass in breast
parenchyma characterized by a rapid growth. Large tumors
can lead to thrombocytopenia and hemorrhagic manifestations
(Kasabach–Merritt syndrome) [8].The typical patient with primary breast angiosarcoma is a young
woman with a dense breast parenchyma.
Imaging of angiosarcoma is not speciﬁc. It is of note that mam-
mogram or ultrasound study do not present proper pathological
ing Group Ltd. This is an open access article under the CC BY-NC-ND license
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attern. AS could be diagnosed as a benign lesion in particular in
oungest patients.
The most supportive imaging exam is considered the magnetic
esonance imaging (MRI) that can show typical malignant signs
hyperintensity on T2 images and a rapid initial intense phase fol-
owed by washout) [9,10].
Fine-needle aspiration or core needle biopsy are necessary to
btain a deﬁnitive diagnosis [10].
In addition immunohistochemistry can be useful to identify the
D31 endothelial, indicator of vascular proliferation. Other speciﬁc
arkers for this kind of lesions are Factor VIII, and FLI1 [11–13].
. Surgical treatment
The gold-standard treatment in patients affected by primary
ngiosarcoma of the breast is surgery consisting in modiﬁed radical
astectomy combined, when necessary, with axillary node dissec-
ion.
Patients with smaller tumors may  beneﬁt of breast-conserving
urgery.
We analyzed surgical indication in series presenting more
han 20 breast sarcoma cases selecting in this way 7 studies
1,9,10,14–18].
In our review we analyzed data on surgical treatment of 251
atients with primary angiosarcoma of the breast: 75% of the
atients underwent mastectomy and 25% underwent breast con-
erving treatment.
Even if it is unlikely that this kind of tumors metastasize to
egional lymph nodes, axillary node dissection was  performed in
2% of all patients.
Rosen et al. presented a series of 63 patients with primary
ngiosarcoma of the breast from the Sloan Kettering Cancer Cen-
er; 35 patients underwent axillary node dissection and only one
resented metastatic lesions [9].
Bousquet et al., Cofraveux et al. and Blanchard et al. presented
heir interesting works describing nodal involvement in less than
0% of cases [10,14,15].
. Chemotherapy
In the available literature there is not an international consensus
bout chemotherapy regimens to be used in patients with angiosar-
oma.
In the article analyzed in this review the use of chemotherapy
aried largely: 36% of patients affected by primary angiosarcoma
eceived chemotherapy as adjuvant or neoadjuvant therapy.
Soft tissue sarcomas are known to be very aggressive tumors:
he probability of the onset of a systemic recurrence is about 50%,
ven in case of localized disease [19].
The medical treatment plays a fundamental role in these
atients as demonstrated by Tierney et al. in their study published
n 1995. An anthracycline-based chemotherapy lead to a signiﬁcant
mprovement of disease free survival and overall survival [20].
Pervaiz et al. demonstrated the importance of adjuvant
oxorubicin-based chemotherapy in delaying local and distant
ecurrence and improving the overall recurrence-free survival [21].
The series presented by Frustaci et al. showed the improvement
n both disease free survival and overall survival using an adjuvant
egimen based on epirubicin plus ifosfamide [22].
In a report published by Sher et al., adjuvant chemother-
py using combinations of anthracycline–ifosfamide or
emcitabine–taxane was administered in more than 60% of
atients with AS of the breast without any improvement in
isease-free survival [16].PEN  ACCESS
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In a more recent work on 41 cases of metastatic angiosarcoma
treated with taxane regimens, Hirata et al. showed an improvement
in overall survival rate [23].
5. Radiation treatment
The role of radiation treatment (RT) is limited to the residual
microscopic disease after surgery of the primary tumor.
The potential impact of RT on local control and survival of
patients with soft tissue sarcomas of other sites has been well
documented.
Adjuvant radiotherapy after surgery may have a beneﬁcial effect
for breast sarcomas, particularly for patients with microscopically
positive margins.
In the analyzed series, 35% percent of the patients have been
treated with adjuvant radiotherapy according to the tumor features
[9,10,14,15].
Rosen et al. used adjuvant radiotherapy in combination with
chemotherapy in 17% of their patients and only radiation in 6% of
their patients without improving disease free survival and overall
survival [9].
In the study by Sher et al., 68% of patients received radiotherapy
with a documented recurrence-free survival of 47% and 44% at 5
and 10 years. This rate shows an improvement in recurrence free
survival compared with patients who did not receive radiotherapy
(33% and 25% at 5 and 10 years respectively) [16].
Even though these results are encouraging, there is not a stat-
ically signiﬁcant correlation between adjuvant radiotherapy and
improved survival due to the small number of included patients.
6. Prognostic factors
The prognosis of the angiosarcoma of the breast, like each his-
totype of sarcoma, is related to the tumor size, the tumor grade and
the resection margin status [13].
Wide excision is mandatory to obtain free margins but even in
this way, it is not easy to join a radical surgery. Most papers show
how an incomplete exeresis is strictly connected with both local
relapse and worst survival [1,10,26–33].
Literature presents different opinions regarding the correlation
between tumor size and prognosis. Most of the authors like Rosen
et al., Bousquet et al., Blanchard et al. and Sher et al. found no
correlation between the size of the primary tumor and the risk of
recurrence or death [9,10,15,16].
On the contrary, other authors, like Adem et al. and Zelek et al.,
underlined in their series of primary sarcoma of the breast the
association between tumor size and disease free survival [1,32].
Another fundamental parameter that has to be analyzed is the
mitotic index deﬁning the tumor grade.
Therefore high-grade sarcomas of the breast present a higher
risk of mortality [24–29].
Bousquet et al., Rosen et al. and Luini et al. in their series proved
that grade I and II lesions were associated with better disease
free survival [9,10,30] while Nascimento et al., in his group of 49
patients with primary angiosarcoma of the breast, demonstrated
no correlation between tumor grade and overall survival [17].
7. Conclusions
Primary angiosarcoma of the breast is a malignant vascular neo-
plasm arising within breast parenchyma with or without extension
into the skin. It should be considered a different neoplasia from
radiation-related AS.
The incidence of primary breast angiosarcoma is approximately
17 new cases per million women [31–33].
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This neoplasia does not present any pathognomonic sign on
ammogram or ultrasound examination and can show speciﬁc
adiological characteristics only at MRI.
There are few available series analyzing the best option for surgi-
al and adjuvant treatment for primary angiosarcoma of the breast.
An aggressive surgical approach seems to be accepted by most
f the authors [1,9,10,15], however breast conserving surgery can
e proposed in selected cases.
Axillary clearance is not necessary in all the patients, in fact
he tumor do not follow a lymphatic way of dissemination; how-
ver bulky masses invading the axilla, necessitate an axillar node
issection in order to achieve free margins.
Even though some series present an increase in disease free
urvival and in the overall survival, standard medical regimens in
atients suffering from breast angiosarcoma remain unclear [16].
djuvant chemotherapy with Taxan agents showed good outcomes
ut more investigations are needed.
Radiotherapy also does not present a clear consensus and should
e considered as adjuvant treatment in selected cases.
Examining the data regarding disease free survival and over-
ll survival, we would like to mention Blanchard study in which
he author compared the outcome for patients with different his-
ological types of breast sarcoma presenting a median disease free
urvival (DFS) of 25 months [4].
Rosen et al. presented a 5-year disease-free survival ranging
rom 15% for patients with high-grade tumors to 76% for those with
ow-grade tumors [9].
The series of Bousquet et al. presented a 5 and 10-year DFS of
7% and 12% respectively [10], while the group from Mayo Clinic
resented a mean survival of 48 months [1].
In conclusion we underline the heterogeneity of surgical and
djuvant therapy proposed for primary AS. Largest series of patients
re requested to reach a shared consensus on the treatment of
rimary angiosarcoma of the breast. We  recommend a multi-
isciplinary approach in which the collaboration of radiologist,
ncologist, breast surgeon, radiotherapist and plastic surgeon could
ead to an evident beneﬁt for patient’s health and quality of life.
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